Evidence map›Paper›PMID 42697217›Full record

Trial reportThe Lancet. Oncology2026

An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

Liam Bourke, Derek J Rosario, Sophie Reale, Said Ibeggazene, Aidan Innes, Alison Scope, Grace Price, Steph Taylor, Liz Steed, Eileen Sutton and 13 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Lancet. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Defining benefit from lifestyle interventions during active surveillance.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Liam BourkeSchool of Health and Social Care, CARe Research Centre, Sheffield Hallam University, Sheffield, UK.
Derek J RosarioSchool of Health and Social Care, CARe Research Centre, Sheffield Hallam University, Sheffield, UK; Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. Electronic address: derek.rosario@nhs.net.
Sophie RealeSchool of Health and Social Care, CARe Research Centre, Sheffield Hallam University, Sheffield, UK.
Said IbeggazeneSchool of Health and Social Care, CARe Research Centre, Sheffield Hallam University, Sheffield, UK.
Aidan InnesNuffield Health, Epsom, Surrey, UK.
Alison ScopeSchool of Health and Social Care, CARe Research Centre, Sheffield Hallam University, Sheffield, UK.
Grace PriceSchool of Health and Social Care, CARe Research Centre, Sheffield Hallam University, Sheffield, UK.
Steph TaylorWolfson Institute of Population Health, Queen Mary University of London, London, UK.
Liz SteedWolfson Institute of Population Health, Queen Mary University of London, London, UK.
Eileen SuttonUniversity of Bristol, Bristol, UK.
Jamie StokesLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Jenny HewisonLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Dylan MorrisseySports and Exercise Medicine, Queen Mary University of London, London, UK; Barts Health NHS Trust, London, UK.
Patrick DohertyDepartment of Health Sciences, University of York, York, UK.
Janet BrownDivision of Clinical Medicine, University of Sheffield, Sheffield, UK.
David MeadsLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
John L O'DwyerLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Davina DeniszczycNuffield Health, Epsom, Surrey, UK.
Diana M GreenfieldSheffield Teaching Hospitals NHS Trust, Sheffield, UK.
Malcolm MasonCardiff University, Cardiff, UK.
Michelle CollinsonLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Amanda FarrinLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK; Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK.
STAMINA investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAndrogen deprivation therapy (ADT) for prostate cancer causes substantial adverse effects. Despite consistent national and international guideline recommendations, supervised exercise is rarely integrated into care. We aimed to determine whether the STAMINA lifestyle intervention, embedded into cancer care, would improve cancer-specific quality of life and fatigue versus behaviourally Optimised Usual Care in men with prostate cancer in England.

methodsSTAMINA was a multicentre, randomised trial done across 15 UK National Health Service (NHS) trusts in England. Men on ADT for prostate cancer were eligible. Participants were randomly assigned (5:4) via computer-generated minimisation, stratified by age, ADT duration, chemotherapy or androgen receptor pathway inhibitor therapy, and radiotherapy, to the STAMINA lifestyle intervention or to Optimised Usual Care. Participants were aware of treatment allocation. The STAMINA lifestyle intervention comprised supervised aerobic and resistance exercise for 12 months, dietary advice, behavioural support, and complimentary gym membership. Optimised Usual Care comprised clinician training, educational materials, behavioural prompts, and safety-to-exercise checks. Primary outcomes were the Functional Assessment of Cancer Therapy-prostate (FACT-P) and the Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) subscale at 12 months, analysed by intention to treat (according to randomised treatment). This trial is registered with ISRCTN (ISRCTN46385239), and recruitment is complete.

findingsBetween Jan 20, 2022, and June 12, 2023, 700 men were randomly assigned to STAMINA lifestyle intervention (n=389) or Optimised Usual Care (n=311). Median age was 71·6 years (IQR 66·3-76·0), and 680 (97%) of 700 participants were White. Primary outcome data were available for 345 (89%) of 389 participants in the STAMINA lifestyle intervention group and 251 (81%) of 311 in the Optimised Usual Care group. The STAMINA lifestyle intervention was superior to Optimised Usual Care in terms of FACT-P score (adjusted mean difference 4·5, 97·232% CI 1·7-7·2; p=0·0004) and FACIT-F score (1·9, 0·4-3·4; p=0·0068). Three intervention-related serious adverse events occurred in the STAMINA lifestyle intervention group (transient loss of consciousness, leg pain or weakness, and back pain); all participants recovered. No treatment-related deaths occurred.

interpretationThe STAMINA lifestyle intervention meets best practice guidelines, can be implemented in NHS trusts in England, and offers clinicians a clear basis for identification and prescription of a supervised exercise and dietary advice intervention to mitigate negative effects associated with ADT.

fundingNational Institute for Health Research.

Indexed as

Androgen AntagonistsFatigueLife StyleProstatic NeoplasmsAgedHumansMaleMiddle AgedQuality of LifeAndrogen Antagonists

Identifiers

PMID42697217
PMCPMC13619545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.